ScreenerHero

ONCIN Oncoinvent ASA

OSL · NO · Healthcare · Biotechnology · oncoinvent.com
82.80NOK-0.48%Mkt Cap: 47.43M $P/E: —

Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
ARGENX SE
$55.45BUSDP/E 35.2
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$42.34BUSDP/E 18.1
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
GMAB
Genmab A/S
$20.52BUSDP/E 27.1
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap47.43M USD
Enterprise Value25.04M USD
Revenue (TTM)2.27M USD
Gross Profit2.27M USD
Net Income (TTM)-14.50M USD
Revenue/Share8.11 NOK
Last Price82.80 NOK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees42
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0013711713
Valuation
P/E (Trailing)—
P/E (Forward)-3.68
PEG—
EV/EBITDA-1.60
EV/Revenue11.02
P/S20.97
P/B2.55
EPS (TTM)-86.19
EPS (Forward)-22.63
52W Range
40.1041% of range144.00
52W High144.00 NOK
52W Low40.10 NOK
Profitability
Gross Margin100.00%
Oper. Margin-841.07%
EBITDA Margin0.00%
Profit Margin-673.13%
ROE-105.98%
ROA-75.66%
Growth
Revenue Growth-31.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.14M USD
CapEx (TTM)11.12K USD
FCF Margin-336.91%
FCF Yield-16.14%
Net Debt-9.79M USD
Net Debt/EBITDA0.63
Balance Sheet
Debt/Equity0.02
Current Ratio2.43
Quick Ratio2.43
Book Value/Sh32.67 NOK
Cash/Share23.84 NOK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 NOK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateJan 19, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)110.00 NOK
Upside (mean)+32.9%
Target Range110.00 NOK – 110.00 NOK
# Analysts1
Ownership
Shares Out.6.13M
Float3.05M
Insiders23.07%
Institutions38.70%
Technical
SMA 5094.23 (-12.1%)
SMA 20059.67 (+38.8%)
Beta—
S&P 52W Chg13.94%
Avg Vol (30d)67.25K
Avg Vol (10d)158.90K
Technical Indicators
RSI (14)38.3
MACD-3.9441
MACD Signal0.7640
MACD Hist.-4.7080
BB Upper150.07 NOK
BB Middle106.83 NOK
BB Lower63.58 NOK
BB Width80.96%
ATR (14)7.834 NOK
Vol Ratio (20d)0.13x